Monday, January 25, 2021
Home Clinical Research Coronavirus treatment: List of Vaccines and drugs in the pipeline for COVID-19

Coronavirus treatment: List of Vaccines and drugs in the pipeline for COVID-19

As the number of confirmed cases of COVID-19 continues to rise, healthcare researchers around the world are working tirelessly to discover new life-saving innovations in medicine.

Here are some companies and institutions developing new treatment options for COVID-19

Vaccine Company name Type of Vaccine Phase of study Study link
mRNA1273  (2019-nCoV Vaccine)   Emory University in Atlanta RNA Phase I
Ad5-nCoV Cansino Bio  Non replicating viral vector Phase I
  chadox1 ncov19 University of Oxford Non replicating viral vector Phase I/II
LVSMENP-DC Shenzhen Geno immune medical institute lentiviral Phase I/II
BCG vaccines (Bacille Calmette-Guérin)   Murdoch Childrens Research Institute. Live Attenuated virus Phase II/III
     Drug Company name Mechanism of action Phase of study Study link
EUSA Pharma interleukin (IL)-6 inhibitor Observational study  
Gimsilumab Roivant monoclonal antibody targeting GM-CSF Phase I
Losartan Univ. of Minnesota ANGIOTENSIN TYPE 1 RECEPTOR inhibitor Phase II
AiRuiKa (camrelizumab) Southeast Univ China PD-1 inhibitor Phase II
Fingolimod    First Affiliated Hospital of Fujian Medical University Sphingosine 1-phosphate receptor modulator Phase II
SNG001 Synairgen IFN-beta 1a Sphingosine phosphate receptor modulator Phase II
Kaletra AbbVie’s HIV protease. Failed trial
Ganovo + Ritonavir Ascletis HCV NS3/4A protease inhibitor. Phase IV
Actemra (Tocilizumab) Roche IL-6 receptors inhibitor Phase III  
CD24Fc Oncoimmune  modulate immune  responses Phase III
Prezcobix Shanghai Public health clinical centre HIV protease inhibitor Phase III
Colchine The Montreal Heart Institute (MHI) Research Centre Tubulin Disruption Phase III
Kevzara (sarilumab) Sanofi and Regeneron IL-6 receptor Phase 2/3
 Hydroxychloroquine University of Minnesota ACE2 inhibitor Phase II/III  
Avigan FUJIFILM RNA polymerase inhibitor Phase III
Avastin (Bevacizumab)  Qilu Hospital of Shandong University VEGF inhibitor Phase 2/3
Remdesivir Gilead Adenosine analouge Phase III
Leronlimab (PRO140) CytoDyn CCR5antagonist Phase 2b/3
Aviptadil NeuroRx IL-6 inhibitor Phase II


Phase III

Mesenchymal stem cells
various instituteTissue regenerationPhase I
- Advertisement -


Please enter your comment!
Please enter your name here

one × three =

Most Popular

Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia

January 25, 2021: "AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult...

What is the process for Submission of Synopsis?

1.1 a. "Prior to submission of a thesis synopsis, a comprehensive assessment of the research work should be carried out by a...

COVAX Announces new agreement, plans for first deliveries

January 22, 2021: COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income...

FDA Approves OPDIVO® with CABOMETYX® as First-line Treatment for advanced Renal Cell Carcinoma

22 Jan 2021:  Bristol Myers Squibb announced that OPDIVO®(nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks...